Literature DB >> 21311643

Synchronous oesophagectomy and hepatic resection for metastatic oesophageal cancer: report of a case.

S S Mudan, A Giakoustidis, D Giakoustidis, M Slevin.   

Abstract

BACKGROUND: Oesophageal cancer with liver metastasis is rare and when diagnosed is usually advanced and surgical management is contraindicated.Method-
Results: We report the case of a patient who presented with oesophageal cancer and liver metastasis. The patient received chemotherapy combined with RFA to liver tumour. Subsequently she was subjected to oesophagectomy and liver resection of segment 5 extended into segment 8. Patient underwent adjuvant chemotherapy post-operatively and remains disease-free until now, 29 months after operation.
CONCLUSION: Oesophageal cancer with concomitant liver metastasis is a rare and lethal disease. Multimodal management including surgery may offer prolonged survival in highly selected patients.

Entities:  

Keywords:  chemotherapy; liver metastasis; oesophageal cancer

Year:  2010        PMID: 21311643      PMCID: PMC3031329     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  9 in total

1.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.

Authors:  Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

2.  Therapeutic strategy for postoperative liver metastasis from esophageal squamous cell carcinoma; clinical efficacy of and problem with hepatic arterial infusion chemotherapy.

Authors:  Y Nakajima; K Nagai; T Kawano; H Inoue; S Nara; Y Kumagai; T Iwai
Journal:  Hepatogastroenterology       Date:  2001 Nov-Dec

3.  Hepatic metastasis from esophageal cancer treated by surgical resection and hepatic arterial infusion chemotherapy.

Authors:  K Hanazaki; T Kuroda; M Wakabayashi; H Sodeyama; S Yokoyama; J Kusama
Journal:  Hepatogastroenterology       Date:  1998 Jan-Feb

4.  Esophagectomy and hepatic arterial chemotherapy following hepatic resection for esophageal cancer with liver metastasis.

Authors:  T Yamamoto; M Tachibana; S Kinugasa; H Yoshimura; N Nagasue
Journal:  J Gastroenterol       Date:  2001-08       Impact factor: 7.527

5.  Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

Authors:  C Pinto; F Di Fabio; S Siena; S Cascinu; F L Rojas Llimpe; C Ceccarelli; V Mutri; L Giannetta; S Giaquinta; C Funaioli; R Berardi; C Longobardi; E Piana; A A Martoni
Journal:  Ann Oncol       Date:  2006-12-12       Impact factor: 32.976

6.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

7.  Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis.

Authors:  Timothy M Pawlik; Ana Luiza Gleisner; Todd W Bauer; Reid B Adams; Srinevas K Reddy; Bryan M Clary; Robert C Martin; Charles R Scoggins; Kenneth K Tanabe; James S Michaelson; David A Kooby; Charles A Staley; Richard D Schulick; Jean-Nicolas Vauthey; Eddie K Abdalla; Steven A Curley; Michael A Choti; Dominque Elias
Journal:  Ann Surg Oncol       Date:  2007-06-06       Impact factor: 5.344

8.  Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases.

Authors:  Eddie K Abdalla; Jean-Nicolas Vauthey; Lee M Ellis; Vickie Ellis; Raphael Pollock; Kristine R Broglio; Kenneth Hess; Steven A Curley
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

9.  Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.

Authors:  Jean-Luc Raoul; Jean-Luc Van Laethem; Marc Peeters; Catherine Brezault; Fares Husseini; Laurent Cals; Johannes Nippgen; Anja-Helena Loos; Philippe Rougier
Journal:  BMC Cancer       Date:  2009-04-14       Impact factor: 4.430

  9 in total
  6 in total

1.  Treatment paradigms and survival outcomes in esophageal adenocarcinoma with liver metastasis: a retrospective cohort study using the SEER database.

Authors:  Jing Guo; Chang-Yong Tong; Jian-Guang Shi; Xin-Jian Li
Journal:  J Gastrointest Oncol       Date:  2022-06

2.  Palliative resection or radiation of primary tumor prolonged survival for metastatic esophageal cancer.

Authors:  Jing Xu; Donghui Lu; Li Zhang; Jian Li; Guoping Sun
Journal:  Cancer Med       Date:  2019-10-14       Impact factor: 4.452

Review 3.  Management of Liver Oligometastatic Esophageal Cancer: Overview and Critical Analysis of the Different Loco-Regional Treatments.

Authors:  Fabio Procopio; Salvatore Marano; Damiano Gentile; Anna Da Roit; Silvia Basato; Pietro Riva; Ferdinando De Vita; Guido Torzilli; Carlo Castoro
Journal:  Cancers (Basel)       Date:  2019-12-19       Impact factor: 6.639

4.  A population-based predictive model predicting candidate for primary tumor surgery in patients with metastatic esophageal cancer.

Authors:  Zhichao Liu; Xiaobin Zhang; Bin Li; Haoyao Jiang; Yang Yang; Rong Hua; Yifeng Sun; Zhigang Li
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

5.  A Model for Identifying Optimal Patients for Primary Tumor Resection in Patients With Metastatic Bladder Cancer.

Authors:  Jintao Hu; Zhenming Zheng; Junjiong Zheng; Weibin Xie; Huabin Su; Jingtian Yang; Zixin Xu; Zefeng Shen; Hao Yu; Xinxiang Fan; Jianqiu Kong; Jinli Han
Journal:  Front Oncol       Date:  2022-01-19       Impact factor: 6.244

6.  A machine learning model predicting candidates for surgical treatment modality in patients with distant metastatic esophageal adenocarcinoma: A propensity score-matched analysis.

Authors:  Fang Liao; Shuangbin Yu; Ying Zhou; Benying Feng
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.